RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at two upcoming investor conferences. Mr. Moch will discuss the company's technology assets and pipeline, including CMX001, a broad-spectrum antiviral being developed for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients and as a biodefense countermeasure in the event of a smallpox release.
Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at 9:50 a.m. ET. Both meetings are being held in New York City.
Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a biodefense countermeasure in the event of a smallpox release. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix-inc.com.
SOURCE Chimerix, Inc.
|SOURCE Chimerix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved